JOP20220079A1 - بروتين ربط متعددة الخصوصية لمعالجة السرطان - Google Patents

بروتين ربط متعددة الخصوصية لمعالجة السرطان

Info

Publication number
JOP20220079A1
JOP20220079A1 JOP/2022/0079A JOP20220079A JOP20220079A1 JO P20220079 A1 JOP20220079 A1 JO P20220079A1 JO P20220079 A JOP20220079 A JO P20220079A JO P20220079 A1 JOP20220079 A1 JO P20220079A1
Authority
JO
Jordan
Prior art keywords
proteins
binding protein
cancer treatment
multispecific binding
express
Prior art date
Application number
JOP/2022/0079A
Other languages
Arabic (ar)
English (en)
Inventor
Rajkumar Ganesan
Pankaj Gupta
Priyanka Gupta
Philip Nicholas Gorman
Michael Dziegelewski
Paul Adam
Justin M Scheer
Vladimir H Voynov
Marcio Lasaro
Susanne Hipp
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=68136317&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JOP20220079(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of JOP20220079A1 publication Critical patent/JOP20220079A1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/82—Colon
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JOP/2022/0079A 2019-10-02 2022-01-31 بروتين ربط متعددة الخصوصية لمعالجة السرطان JOP20220079A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19201200 2019-10-02
PCT/EP2020/077586 WO2021064137A2 (en) 2019-10-02 2020-10-01 Multi-specific binding proteins for cancer treatment

Publications (1)

Publication Number Publication Date
JOP20220079A1 true JOP20220079A1 (ar) 2023-01-30

Family

ID=68136317

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2022/0079A JOP20220079A1 (ar) 2019-10-02 2022-01-31 بروتين ربط متعددة الخصوصية لمعالجة السرطان

Country Status (24)

Country Link
US (2) US11732045B2 (cg-RX-API-DMAC10.html)
EP (1) EP4038100A2 (cg-RX-API-DMAC10.html)
JP (2) JP7387885B2 (cg-RX-API-DMAC10.html)
KR (1) KR20220075383A (cg-RX-API-DMAC10.html)
CN (4) CN122103354A (cg-RX-API-DMAC10.html)
AR (1) AR120138A1 (cg-RX-API-DMAC10.html)
AU (1) AU2020358893A1 (cg-RX-API-DMAC10.html)
BR (1) BR112022004047A2 (cg-RX-API-DMAC10.html)
CA (1) CA3153372A1 (cg-RX-API-DMAC10.html)
CL (1) CL2022000664A1 (cg-RX-API-DMAC10.html)
CO (1) CO2022003552A2 (cg-RX-API-DMAC10.html)
CR (1) CR20220136A (cg-RX-API-DMAC10.html)
DO (1) DOP2022000060A (cg-RX-API-DMAC10.html)
EC (1) ECSP22019193A (cg-RX-API-DMAC10.html)
IL (1) IL291817A (cg-RX-API-DMAC10.html)
JO (1) JOP20220079A1 (cg-RX-API-DMAC10.html)
MX (1) MX2022004042A (cg-RX-API-DMAC10.html)
MY (1) MY209387A (cg-RX-API-DMAC10.html)
PE (1) PE20221412A1 (cg-RX-API-DMAC10.html)
PH (1) PH12022550693A1 (cg-RX-API-DMAC10.html)
SA (1) SA522432139B1 (cg-RX-API-DMAC10.html)
TW (1) TWI878355B (cg-RX-API-DMAC10.html)
UA (1) UA130106C2 (cg-RX-API-DMAC10.html)
WO (1) WO2021064137A2 (cg-RX-API-DMAC10.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023504675A (ja) 2020-05-19 2023-02-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ガンの処置のための結合分子
CN117321087A (zh) 2021-03-26 2023-12-29 先天制药公司 包含与细胞因子融合用于nk细胞衔接的nkp46结合位点、癌抗原结合位点的多特异性蛋白质
US12065427B2 (en) 2021-04-29 2024-08-20 Boehringer Ingelheim International Gmbh Heterocyclic compounds capable of activating STING
WO2022258678A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a
CN117616050A (zh) 2021-06-09 2024-02-27 先天制药公司 与nkp46、细胞因子受体、肿瘤抗原和cd16a结合的多特异性蛋白质
WO2022258691A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a
CN114395045B (zh) * 2021-12-07 2023-06-09 合肥天港免疫药物有限公司 B7h6抗体及其应用
CN114395047B (zh) * 2021-12-07 2023-11-07 合肥天港免疫药物有限公司 双特异性抗体及其应用
CN114395043B (zh) * 2021-12-07 2023-07-11 合肥天港免疫药物有限公司 Ncr3lg1抗体及其应用
US20240174642A1 (en) 2022-10-26 2024-05-30 Boehringer Ingelheim International Gmbh Heterocyclic compounds capable of activating sting
WO2024088991A1 (en) 2022-10-26 2024-05-02 Boehringer Ingelheim International Gmbh Heterocyclic compounds capable of activating sting
AU2023370123A1 (en) 2022-10-26 2025-04-17 Boehringer Ingelheim International Gmbh Heterocyclic compounds capable of activating sting
WO2024208818A1 (en) 2023-04-04 2024-10-10 Innate Pharma Modular chimeric antigen receptor

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5731A (en) 1848-08-22 Elisha k
US168A (en) 1837-04-17 Improvement in fire-arms
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
FI903489A7 (fi) 1988-11-11 1990-07-10 Medical Res Council Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
WO1994003678A1 (en) 1992-08-10 1994-02-17 Alcan Aluminium Uk Limited Fence
DE69334275D1 (de) 1992-08-21 2009-05-20 Univ Bruxelles Immunoglobuline ohne Leichtkette
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
CA2163032C (en) 1993-06-03 2001-02-06 John Landon Antibody fragments in therapy
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
EP1361892A4 (en) 2001-01-17 2004-10-13 Trubion Pharmaceuticals Inc BINDING DOMAIN FUSION PROTEIN Immunoglobulin
EP1456410A2 (en) 2001-12-11 2004-09-15 AlgoNomics N.V. Method for displaying loops from immunoglobulin domains in different contexts
NL1019562C2 (nl) 2001-12-13 2003-06-17 Heineken Tech Services Klepsamenstel voor gebruik bij drankafgifte.
US8764654B2 (en) 2008-03-19 2014-07-01 Zin Technologies, Inc. Data acquisition for modular biometric monitoring system
US8236308B2 (en) * 2005-10-11 2012-08-07 Micromet Ag Composition comprising cross-species-specific antibodies and uses thereof
CN101287764B (zh) 2005-10-12 2013-11-13 莫佛塞斯公司 特异性针对人CD38的完全人HuCAL GOLD-衍生治疗抗体的生成和鉴定
US7858759B2 (en) 2007-10-04 2010-12-28 Zymogenetics, Inc. Anti-zB7H6 antibody-drug conjugates
EP3663318A1 (en) 2008-01-07 2020-06-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
FI20090280L (fi) 2009-07-17 2011-01-18 Kone Corp Hissijärjestely ja menetelmä hissikorin liikuttamiseksi hissikuilussa
CA2777527C (en) 2009-12-23 2020-06-23 Esbatech, An Alcon Biomedical Research Unit Llc Method for decreasing immunogenicity
WO2012162067A2 (en) 2011-05-21 2012-11-29 Macrogenics, Inc. Cd3-binding molecules capable of binding to human and non-human cd3
CA3141978A1 (en) 2011-06-23 2012-12-27 Ablynx Nv Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
MY167125A (en) 2011-08-17 2018-08-13 Glaxo Group Ltd Modified proteins and peptides
DK2766392T3 (da) * 2011-10-10 2019-10-07 Xencor Inc Fremgangsmåde til oprensning af antistoffer
CN104395344B (zh) * 2012-05-07 2019-08-13 达特茅斯大学理事会 抗b7-h6抗体、融合蛋白及其使用方法
CN104640561A (zh) * 2012-07-23 2015-05-20 酵活有限公司 包含轻链和重链的选择性配对的免疫球蛋白构建体
US11291721B2 (en) * 2016-03-21 2022-04-05 Marengo Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
CN114634569B (zh) * 2016-04-15 2024-08-20 达特茅斯大学理事会 高亲和力b7-h6抗体和抗体片段
EP3848393A1 (en) 2016-05-18 2021-07-14 Boehringer Ingelheim International GmbH Antibody molecules for cancer treatment
TWI848953B (zh) * 2018-06-09 2024-07-21 德商百靈佳殷格翰國際股份有限公司 針對癌症治療之多特異性結合蛋白

Also Published As

Publication number Publication date
WO2021064137A2 (en) 2021-04-08
PE20221412A1 (es) 2022-09-20
CN122277744A (zh) 2026-06-26
CN114641496A (zh) 2022-06-17
AR120138A1 (es) 2022-02-02
TW202128756A (zh) 2021-08-01
CA3153372A1 (en) 2021-04-08
JP7809680B2 (ja) 2026-02-02
TWI878355B (zh) 2025-04-01
JP7387885B2 (ja) 2023-11-28
ECSP22019193A (es) 2022-04-29
CN122080223A (zh) 2026-05-26
US20230340130A1 (en) 2023-10-26
JP2024020414A (ja) 2024-02-14
UA130106C2 (uk) 2025-11-12
US11732045B2 (en) 2023-08-22
MX2022004042A (es) 2022-05-02
BR112022004047A2 (pt) 2022-05-24
SA522432139B1 (ar) 2024-08-29
CO2022003552A2 (es) 2022-04-19
CN114641496B (zh) 2026-01-02
EP4038100A2 (en) 2022-08-10
DOP2022000060A (es) 2022-05-31
JP2022551081A (ja) 2022-12-07
CL2022000664A1 (es) 2023-01-06
US20210107983A1 (en) 2021-04-15
CR20220136A (es) 2022-05-27
KR20220075383A (ko) 2022-06-08
MY209387A (en) 2025-07-07
AU2020358893A1 (en) 2022-03-31
WO2021064137A3 (en) 2021-05-14
PH12022550693A1 (en) 2023-03-27
CN122103354A (zh) 2026-05-29
IL291817A (en) 2022-06-01

Similar Documents

Publication Publication Date Title
SA522432139B1 (ar) بروتينات ربط متعددة الخصوصية لمعالجة السرطان
JOP20200313A1 (ar) أجسام مضادة dll3-cd3 ثنائية الخاصية
SA518400424B1 (ar) جزيئات الجسم المضاد لعلاج السرطان
MX2021003554A (es) Proteinas de union a dll3 y metodos de uso.
PH12020551907A1 (en) Antagonizing cd73 antibody
MX2019006045A (es) Proteinas triespecificas dirigidas a psma y metodos de uso.
EA202090817A1 (ru) Триспецифические белки и способы их применения
PH12019500122A1 (en) Bispecific antibody-like binding proteins specifically binding to cd3 and cd123
EA201792573A1 (ru) Триспецифические связанные белки и способы их применения
PH12019500571A1 (en) Anti-pd-1 antibodies
PH12019500596A1 (en) Recombinant binding proteins and their use
EA202190267A1 (ru) Способы и композиции с использованием рекомбинантных дендритных клеток для терапии рака
PH12018502400A1 (en) Anti-tim-3 antibodies and methods of use thereof
MX2020009550A (es) Proteinas de union a antigeno antagonistas.
WO2022236276A3 (en) Anti-tigit antibodies, anti-cd96 antibodies, and methods of use thereof
WO2021043810A8 (en) Anti-fucosyl-gm1 antibodies
EA202092928A1 (ru) Dll3-cd3 биспецифические антитела
EA201991181A1 (ru) Psma-нацеленные триспецифические белки и способы их применения
AR115506A1 (es) Proteínas de fijación multiespecífica para el tratamiento del cáncer
EA201992692A1 (ru) Нацеленные на msln триспецифические белки и способы применения